You are here

Kymriah

Novartis takes another step forward in global Kymriah rollout as Japan OKs the drug at $305K

Novartis takes another step forward in global Kymriah rollout as Japan OKs the drug at $305K

Endpoints

Flag link:

Medicare would cover CAR-T cell therapies under new CMS proposal

Medicare would cover CAR-T cell therapies under new CMS proposal

Marketwatch

Gilead Sciences

Flag link:

Oncology round-up: CAR-T conference raises hopes for solid tumour therapy

Oncology round-up: CAR-T conference raises hopes for solid tumour therapy

Pharmaforum

Flag link:

Novartis changes NICE's mind on Kymriah, giving CAR-T rival Gilead some company

Novartis changes NICE's mind on Kymriah, giving CAR-T rival Gilead some company

Fierce Pharma

diffuse large B-cell lymphoma

Gilead Sciences

Flag link:

Massachusetts Initiative Looks at Payment Plans for Novartis' SMA Gene Therapy

Massachusetts Initiative Looks at Payment Plans for Novartis' SMA Gene Therapy

BioSpace

Flag link:

Novartis building out cell and gene therapy platform that'll lead the pack, CEO promises

Novartis building out cell and gene therapy platform that'll lead the pack, CEO promises

Fierce Pharma

Flag link:

For CAR-T Cancer Fighters in the Real World, Two Roads Diverge

For CAR-T Cancer Fighters in the Real World, Two Roads Diverge

Xconomy

Gilead Sciences

Flag link:

Novartis seeks to acquire French CAR-T contract manufacturer

Novartis seeks to acquire French CAR-T contract manufacturer

Biopharma Dive

Flag link:

Novartis, still struggling with Kymriah manufacturing, is providing some out-of-spec doses to patients who ask

Novartis, still struggling with Kymriah manufacturing, is providing some out-of-spec doses to patients who ask

Fierce Pharma

drug manufacturing

Flag link:

2 Sets of Disasters Biotech Will Pay For in 2019

2 Sets of Disasters Biotech Will Pay For in 2019

Yahoo/Motley Fool

Gilead Sciences

Spark Therapeutics

Flag link:

ASH: Gilead, Novartis tout long-term data for CAR-T slow starters Yescarta, Kymriah

ASH: Gilead, Novartis tout long-term data for CAR-T slow starters Yescarta, Kymriah

Fierce Pharma

Flag link:

Novartis’ CAR-T cancer drug available on NHS to young people

Novartis’ CAR-T cancer drug available on NHS to young people

Pharmaforum

refractory B-cell acute lymphoblastic leukemia

Flag link:

Insight: How Novartis built a ‘money-filled moat’ to market Kymriah

Insight: How Novartis built a ‘money-filled moat’ to market Kymriah

Biopharma Reporter

Flag link:

Novartis signs manufacturing deal for Kymriah in China

Novartis signs manufacturing deal for Kymriah in China

BioCentury

drug manufacturing

Flag link:

NICE rejects Novartis’ CAR-T in adult lymphoma

NICE rejects Novartis’ CAR-T in adult lymphoma

Pharmaforum

diffuse large B-cell lymphoma

Flag link:

Novartis CAR-T therapy snags UK coverage, cutting list price 23% from US

Novartis CAR-T therapy snags UK coverage, cutting list price 23% from US

Biopharma Dive

Flag link:

Novartis announces new €78m plant and 450 new jobs to manufacture Kymriah in EU

Novartis announces new €78m plant and 450 new jobs to manufacture Kymriah in EU

GoinPharma

acute lymphoblastic leukemia

Flag link:

Novartis wins a key OK for Kymriah, but continuing manufacturing woes hobble rollout — rival Gilead CAR-T breaks into Europe

Novartis wins a key OK for Kymriah, but continuing manufacturing woes hobble rollout — rival Gilead CAR-T breaks into Europe

Endpoints

drug manufacturing

Flag link:

Kymriah Manufacturing Issues Spell Trouble for Commercialization of Novartis CAR-T Therapy

Kymriah Manufacturing Issues Spell Trouble for Commercialization of Novartis CAR-T Therapy

Xtalks

drug manufacturing

Flag link:

Could an old Amgen-developed RA drug make CAR-T treatments safer?

Could an old Amgen-developed RA drug make CAR-T treatments safer?

Fierce Biotech

cytokine release syndrome

Flag link:

Pages